Product Liability Lawyer Blog

April 30, 2014

Hypogonadism and the Risks of Testosterone Therapy

As men age, their levels of testosterone can decrease, resulting in lower muscle mass, lack of energy, and other physical symptoms that may go beyond the expected symptoms of aging. While all men will go through some loss of testosterone, other men may be diagnosed with a medical condition known as hypogonadism, a syndrome that up until now has gone undiagnosed.

According to medical reports, hypogonadism is associated with Klinefelter syndrome, a medical condition that occurs in 1 in 500-600 boys. For those who suffer from the condition, hormone replacement therapies can bring testosterone up to normal levels.

With an increased awareness of congenital hypogonadism, researchers and doctor are exploring potential treatment options. Testosterone therapy has been a common form of treatment for hypogonadism, but it has also been overprescribed and often used by men who do not suffer from hypogonadism. This may a significant risk of cardiovascular issues, including heart attack. Our medical malpractice attorneys in Boston are experienced in investigating complex products liability cases and in pursuing financial compensation for victims. We understand the risks of testosterone therapy and are dedicated to raising awareness and helping prevent future injuries associated with dangerous drugs.
Continue reading

April 25, 2014

Study Confirms Alarming Failure Rate of Stryker Rejuvenate

by Jeffrey S. Glassman

Nationwide, patients, doctors, and manufacturers are becoming more aware of the potential risks of knee and hip implants. For the victims of the defective medical devices, the realization may come after severe pain, complications, and the need for reconstructive or rehabilitative surgeries. In a new medical study published in The Journal of Bone & Joint Surgery, researchers conclude that the Stryker Rejuvenate systems had high rates of failure between June of 2009 and July of 2012. During this time, 28% of patients who received hip implants had to return for revision surgery. According to the authors, the patients of the study had their surgery performed by an experienced and skilled surgeon.

Patients who have suffered from hip replacement complications may entitled to significant compensation. Our Boston hip implant attorneys are dedicated to raising awareness and to helping our clients move forward after a defective hip replacement. We understand that significant pain, loss, and expense of defective medical devices and will take every necessary step to protect your rights and interests. Though the risks of Stryker hip implants have been known for years, this study confirms the alarming rate at which patients suffer failure.
Continue reading

April 21, 2014

FDA Approves Drug to Prevent Pulmonary Embolism for Implant Patients

by Jeffrey S. Glassman

As an increasing number of Americans are faced with the difficult decision of whether to pursue hip or knee replacements, an increasing number of cases involving complications. This has given rise to hundreds of thousands of lawsuits, millions in medical expenses, and ongoing health issues for patients. Now Bristol-Meyers Squibb has announced that the U.S. Food and Drug Administration has approved a new supplemental drug for deep vain thrombosis, which could result in pulmonary embolism in patients who have undergone hip or knee replacement surgery.

The new drug, known as Eliquis is intended to prevent deep pain thrombosis in patients who have undergone hip or knee replacement. Advocates for the drug claim that the approval is a significant milestone for the medication and for the patients who suffer from additional health risks associated with knee and hip implants. Our Boston products liability attorneys are dedicated to helping victims or defective or dangerous products recover just compensation for their injuries. In addition to pursuing financial claims, we are committed to raising awareness surrounding the complications associated with medical device injury.
Continue reading

April 18, 2014

Jury Awards $6 Billion in Punitive Damages Against Takeda

by Jeffrey S. Glassman

A federal jury has ordered Takeda Pharmaceutical Co. and Eli Lilly & Co. to pay a combined $9 billion in punitive damages after finding that the companies hid the risks of cancer in their diabetes drug trial held in the United States. This makes the jury award the seventh-largest in U.S. history. The Osaka-Japan based company may be forced to pay the final judgment in the case, even covering the $3 billion ordered paid by its partner company Eli Lilly in Indianapolis. The company lost 5.2 percent of its shares, the biggest drop since last year.

This giant award is a signal to other companies that juries and courts are willing to hold them accountable for egregious deceit of consumers. Our defective drug attorneys are dedicated to protecting the rights of victims who have suffered because of dangerous and defective products, or failure to warn. We take an informed and strategic approach to understand the facts of every case and will aggressively pursue relevant legal claims against liable companies. In addition to advocating for our clients, we are abreast of products liability legal developments, locally and nationally.
Continue reading

April 16, 2014

Wrongful Death Lawsuit: Heart Attack Linked to Testosterone Therapy

by Jeffrey S. Glassman

Testosterone therapy is increasingly under scrutiny for the cardiovascular risks posed patients. In a recent case, a family has filed a wrongful death lawsuit against the Testim gel manufacturer after a 61-year-old man suffered a heart attack and died after suffering negative effects of testosterone replacement therapy. The lawsuit was filed by the family of the victim against Auxilium Pharmaceuticals in the U.S. District Court for the Eastern District of Louisiana. Due to the rising number of injuries and deaths related to testosterone therapy, there have been nearly 100 similar cases filed against manufacturers nationwide.

Hormone therapy has been marketed to men who have suffered side effects of decreased levels of testosterone with aging. The condition, also known as “Low T” has been treated with prescriptions of Testim and other testosterone therapy drugs. With the widespread marketing and growing popularity of these drugs, sales have reached approximately $2 billion in recent years. Our Boston dangerous drugs attorney are dedicated to protecting the rights of victims. We stay abreast of injury trends in pharmaceuticals and are dedicated to bringing justice to families.
Continue reading

April 11, 2014

Age Increases Pelvic Organ Prolapse Risk but TVM May Not be the Answer

by Jeffrey S. Glassman

Pelvic organ prolapse (POP) is a serious medical condition that affects many women. Recent articles indicate that as many as 50 percent of all women between the ages of 50 and 79 experience some type of prolapse in the pelvic organs. As women age, the risk of prolapse significantly increases and can cause bothersome symptoms that lead women to seek medical treatment.

Vaginal mesh products became a popular product for treating POP as well as another condition called stress urinary incontinence (SUI). The mesh products, including vaginal slings, were used to provide support to the organs that were beginning to prolapse.
Continue reading

April 8, 2014

$1.2 Million Vaginal Mesh Verdict for Plaintiff

by Jeffrey S. Glassman

A 64-year-old woman was recently awarded $1.2 million in a transvaginal mesh case against Johnson & Johnson. The jury determined that the plaintiff had suffered damages because the vaginal-mesh implant the woman received was defectively designed and was responsible for causing the her injuries.

The claim against Johnson & Johnson was based on a product called the TVT-O mesh sling. While the jury found for the plaintiff that the device was defective, they rejected the plaintiff’s claims that Johnson & Johnson failed to provide adequate warning about health risks associated with the sling. No punitive damages were awarded.
Continue reading

April 5, 2014

FDA Reports Dramatic Increase in Medical Device Recalls

by Jeffrey S. Glassman

Medical device recalls have increased dramatically in the past 10 years. A detailed report provided by the Food and Drug Administration (FDA) indicated that there was a 97 percent increase in the number of medical devices recalled annually from fiscal year 2003 to fiscal year 2012.

The FDA attributes the increase in recalls to enhanced awareness by medical device firms, especially those firms that were cited repeatedly for violations of safety rules and standards. Efforts by the Center for Devices and Radiological Health (CDRH) to improve device safety were also listed as a reason for the higher recall numbers.
Continue reading

April 3, 2014

Stryker Hip Settlements Reached

by Jeffrey S. Glassman

Stryker hip replacement products have prompted more than 1,500 lawsuits nationwide by patients alleging problems with hip replacement devices. Recently, eight of these cases settled. Because of confidentiality agreements, North Jersey.com reports that it’s not clear how much money was recovered by the plaintiffs. Still, the settlements provide hope to other patients affected by Stryker hip problems because the victims of these defective joint replacements were at least able to recover some money for their damages and losses.

The cases that settled are important because they did so as part of a court-ordered mediation process that took place in a Superior Court in Burgen County, New Jersey. More than half of all Stryker cases have been consolidated in this court under Judge Brian Martinotti. The cases are part of a multi-county litigation (MCL). Remaining cases in the MCL will continue to move forward, with a second phase of mediation expected to follow.
Continue reading

March 31, 2014

Coloplast to Settle Vaginal Mesh lawsuits for $16 Million

by Jeffrey S. Glassman

Coloplast is one of more than 30 manufacturers of vaginal mesh responsible for putting millions of women at risk. Transvaginal mesh (TVM) is used to treat pelvic organ prolapse (POP) and stress urinary continence (SUI), and Bloomberg reports that one manufacturer indicated that more than a million women have had mesh implanted over the past 15 years.

Unfortunately, vaginal mesh can begin to erode in the body and can fail to work as required for women. The mesh can cause women to experience significant pain, including discomfort during sexual intercourse. Vaginal mesh may also not be effective in treating POP, as many women experience recurrent prolapse of pelvic organs. Because of the myriad problems identified with vaginal mesh, the Food and Drug Administration issued an order in 2012 requiring manufacturers of mesh products to conduct studies to identify the rates of complications. These studies should assess how likely it is that the mesh will cause organ damage and other serious health problems.
Continue reading